B. Riley Forecasts biote’s Q3 Earnings (NASDAQ:BTMD)

biote Corp. (NASDAQ:BTMD) – Research analysts at B. Riley issued their Q3 2025 earnings per share estimates for shares of biote in a research note issued to investors on Thursday, March 13th. B. Riley analyst J. Van. Sinderen anticipates that the company will post earnings per share of $0.10 for the quarter. The consensus estimate for biote’s current full-year earnings is $0.75 per share. B. Riley also issued estimates for biote’s Q4 2025 earnings at $0.10 EPS.

Separately, Craig Hallum dropped their price target on shares of biote from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday.

biote Stock Up 22.5 %

Shares of BTMD stock opened at $3.76 on Friday. The firm has a market capitalization of $204.31 million, a P/E ratio of 14.46 and a beta of 1.07. biote has a twelve month low of $3.04 and a twelve month high of $8.44. The stock’s fifty day simple moving average is $4.96 and its 200 day simple moving average is $5.55.

Hedge Funds Weigh In On biote

Hedge funds and other institutional investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD acquired a new position in biote in the fourth quarter valued at $67,000. Commonwealth Equity Services LLC acquired a new stake in biote in the fourth quarter worth $68,000. Public Employees Retirement System of Ohio bought a new stake in biote in the fourth quarter valued at $69,000. Intech Investment Management LLC bought a new stake in biote in the fourth quarter valued at $71,000. Finally, SG Americas Securities LLC acquired a new position in shares of biote during the fourth quarter valued at about $76,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.